# TRANSLATION PATENT COOPERATION TREATY

# ENTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

		4.6				
Applicant's or agent's file reference C1-A0323P			reference	FOR FURTHER ACTION	DN	See Form PCT/IPEA/416
International application No.			No.	International filing date (de	y/month/year)	Priority date (day/month/year)
			018501	10.12.2004		12.12.2003
Internat	tional Pr	teni Class	ification (IPC) or nati	onal classification and IPC		
CO7K16/28, C12N16/00, C12N1/15, C12N1/19, C12N1/21, C12N5/00, C12P21/02, A61R98/395, A61P35/00, A61P35/02, A61P37/02, A61P37/02,						
CHUGAI SEIYAKU KABUSHIKI KAISHA						
1.	under	Article 35	and transmitted to the	applicant according to Arti		international Preliminary Examining Authority
2.	This i	REPORT	onsists of a total of _	7	sheets. Including	this cover sheet.
3.	This	eport is al	so accompanied by Al	NEXES, comprising:		1
	. E	] (80	t to the applicant and	o the International Bureau)	a total of	sheets, as follows:
		_ (				mended and are the basis for this report and/or
		ш	sheets containing rec Instructions).	tifications authorized by thi	s Authority (see Rul	le 70.16 and Section 607 of the Administrative
	sheets which supersede earlier theets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.					
	. г	٦.				
	ь. L	(seni	to the international E	ureau only) a total of (indic	ate type and number	of electronic carrier(s))
						, containing a sequence listing and/or tables
			thereto, in computer 802 of the Administr		cated in the Suppler	mental Box Relating to Sequence Listing (see
4.	Thisn	port cont	sins indications relatin	g to the following items:		
	$\boxtimes$	Box No.	1 Basis of the	eport		
		Box No.	II Priority			
		Box No.	III Non-establis	ment of opinion with regar	d to novelty, inventi	ve step and industrial applicability
		Box No.	IV Lack of units	of invention		
	$\boxtimes$	Box No.	V Reasoned sta			ly, inventive step or industrial applicability:
		Box No.				
	$\tilde{\Box}$	Box No.		ts in the international applic	ation	)
	$\bar{\Box}$	Box No.		vations on the international		
Date of	=					
Date of submission of the demand Date				Date	of completion of this	report
·	Name and mailing address of the IPEA/JP					
Name and maring address of the IPDADE				Autho	rized officer	ļ
				l		
				j		j
Facsimile No.			Telep	hone No.		

Во	α No.		Basis of the report	
ı.			to the language, this report is based on the international apider this item.	optication in the language in which it was filed, unless otherwise
	This report is based on translations from the original language into the following			
	_	$\Box$	is the language of a translation furnished for the purposes of	of:
			international search (Rule 12.3 and 23.1(b))	
		$\Box$	publication of the international application (Rule 12.4)	
١.	1175		international preliminary examination (Rule 55.2 and/or 55	
2.	With repart to the elements of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not awareed to this report;			
	$\bowtie$	the inte	ernational application as originally filed/furnished	
	Ш	the des	scription	
		pages		as originally filed/fornished
		page s*		ived by this Authority on
		pages*	· rece	lved by this Authority on
		the clai	ims:	
		nos.		as originally filed/fornished
		nos.*		as amended (together with any statement) under Article 19
		nos.*		ived by this Authority on
		nor.	rece	lved by this Authority on
		the draw	wings:	
		sheets		as originally filed/furnished
		sheets*	rece	ved by this Authority on
		sheets*		ved by this Authority on
		a seque:	nce listing and/or any related table(s) - see Supplemental E	
3.			nendments have resulted in the cancellation of:	
	_	$\overline{}$	ne description, pages	
		_	he claims, nos.	
		$\overline{}$	ne drawings, sheets/figs	
		$\overline{}$	ne sequence listing (specify):	
		$\overline{}$	ny table(s) related to sequence listing (specify):	
4.		This rep		annexed to this report and listed below had not been made, since indicated in the Supplemental Box (Rule 70.2(c)).
		☐ ıb	ne description, pages	
		$\neg$	ne claims, nos.	
		ın	et drawings, sheets/figs	
		_		
	-		ny table(s) related to sequence listing (specify):	
•	If ites	n 4 appli	ies, some or all of those sheets may be marked "superseded	·

Ва	X No. V Ressoned statement citations and expla	it under Article 35(2) with regard to novelty, inventive step or industrial applicability; mations supporting such statement	
J.	Statement		
	Novelty (N)	Claims 1-28	YES
		Claims	NO
	Inventive step (IS)	Claims 15	VES
		1 14 16 00	NO
	Industrial applicability (IA)	1-29	
	maaman approachis (ort)	Claims 1-28	
2.	Citations and explanations (Rule 7	10.7)	
	Documents 1 to	6 below were cited in the international	
	search report:		
	Document 1: Sek	imoto E. et al., Blood, November 2003,	
	Vol	1. 102, No. 11, page 933a, Abstract, #3474	
	Document 2: Kip	riyanov, S.M. et al., J. Mol. Biol., June	
	200	3, Vol. 330, No. 1, pages 99 to 111	
	Document 3: Lau	rent Genestier et al., Blood, 1997, Vol.	
	90,	No. 9, pages 3629 to 3639	
	Document 4: Hud	son P.J. et al., J. Immunol. Methods,	
	199	9, Vol. 231, No. 1-2, pages 177 to 189.	
	Rev	riew	
	Document 5: JP	7-503622 A (The Dow Chemical Company), 20	
	Apr	il 1995, entire description	
	Document 6: CO 1	M.S. et al., J. Immunol., 1994, Vol. 152,	
	No.	6, pages 2968 to 2976	
	Document 1	sets forth a monoclonal antibody (2D7),	
	and indicates th	nat said monoclonal antibody recognizes	
	HLA class I HLA-	-A.	
	Document 2	sets forth a bispecific scFV antibody	
	containing two	variable heavy chain domains and two	
	variable light (	chain domains (see fig. 1, etc.).	
	Document 3	sets forth MoAb90 and YTH862, which are	

International application No.
PCT/JP2004/018501

Box No. V Reasoned s

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;

distins and explanations supporting such statement
monoclonal antibodies for human HLA class IA.

nocional antibodies for human HLA class IA.

Documents 4 and 5 both disclose sc(Fv)2.

Document 6 sets forth a method of obtaining DNA which codes monoclonal antibodies.

The invention set forth in claims 1 to 28 involves an inventive step in relation to documents 1 to 6.

The invention set forth in claims 1 to 28 of this application is not disclosed in documents 1 to 6.

The invention set forth in claims 1 to 14 and 16 to 28 does not involve an inventive step in the light of a combination of documents 1, 2 and 6.

It would be easy for a person skilled in the art to use the method set forth in document 6 to obtain the DNA which codes a monoclonal antibody (2D7) set forth in document 1, and to prepare a bispecific scFv antibody of the monoclonal antibody (2D7) using the method for preparing a bispecific scFv set forth in document 2 from the DNA thus obtained.

The invention set forth in claim 1 to 7 and 17 to 28 does not involve an inventive step in the light of a combination of documents 3 to 6. It would be easy for a person skilled in the art to conceive of using the method set forth in document 6 to obtain DNA which codes the monoclonal antibodies MoAb90 and YTH862 set forth in document 3, and to prepare the sc(Fv)2 of the monoclonal antibodies MoAb90 and YTH862 using the methods of preparing sc(Fv)2 set forth in documents 4 and 5 from the DNA thus obtained.

International application No. PCT/JP2004/018501

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

The invention set forth in claim 15 involves an inventive step in relation to documents 1 to 6.

The sc(Fv)2 having the amino acid sequence set forth in SEQ ID NO: 2 described in claim 15 is an sc(Fv)2 of a monoclonal antibody (2D7), but said sc(FV)2, as set forth in fig. 4 and 5, has the same activity as 2D7DB which is a diabody of the monoclonal antibody (2D7), and as shown in fig. 6, markedly improves the stability in the blood, and a person skilled in the art would not be able to predict this feature.

Supplemental Box Relating to Sequence Listing			
Continuation of Box No. I, item 2:			
With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed inversion, this report was established on the basis of:			
a. type of material a requence listing table(1) related to the sequence listing  from the formate late in computer readable form  c. time of filling/furnishing contained in the international application as filed filled together with the International application in computer readable form  furnished subsequently to this Authority for the purposes of search and/or examination received by this Authority as an amendment of			
Indicates of the Automater as an anconcern on     Indicate the required fracements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed. as appropriate, were furnished.			
3. Additional comments:			
* If item 4 in Box No. I applies, the litting andler tablets) related thereto, which form part of the basis of the report, may be marked			

	FC1/0F2004/010301
Supplemental Box	
In case the space in any of the preceding boxes is not sufficient.  Continuation of:	
(IPC) Int.Cl.7	
A61P13/00, C12P21/08	